Pages
Thursday, April 5, 2012
202兵工廠案…張曉風翁啟惠難得 “異見” 相同!
台北市糖尿病就醫154635人!
糖尿病改善方案僅2成患者加入‧聯合新聞網2012/04/04【聯合報╱記者陳雅芃/台北報導】衛生署健康保險局推出「全民健康保險糖尿病醫療給付改善方案」,針對糖尿病人設計「以病人為中心」的整合型照護模式。依衛生署研究,參加此方案的糖尿病個案各項生理指標,皆較加入時有顯著改善。不過根據統計,北市去年糖尿病就醫人數有15萬4635人,只有3萬675病患參加「全民健保糖尿病醫療給付改善方案」,比例約2成。台北市衛生局健康管理處長林莉茹表示,研究發現,參加者血糖、血壓、血脂,皆較加入時有顯著改善,接受1年照護後的糖化血色素約可降低0.3%。林莉茹也說,參與此方案有一定條件,例如醫療院所要加入這方案,病患個人近3個月內,在該院所同醫師診斷為糖尿病至少就醫達2次以上,才可加入方案。另外,林莉茹說,許多病患通常接受慢性處方箋,不想定期參加此方案的相關檢測事宜。她強調,只要有加入健保的病患,不需要額外付費,呼籲糖尿病患為獲得更好的照護品質,應及早參加此方案。
朱澤民質疑 六大類所得補充保費!!
何謂醫美保養品…?
醫學產品口碑立大功【2012/04/06經濟日報】隨著經濟景氣的消長,M型化社會之下的M型消費,讓醫學美容保養品愈來愈受消費者青睞,伴隨臉部微整型的興起,也讓具有類似效果的醫美產品,買氣更佳暢旺。康是美總經理高敏航指出,M型化社會讓美容保養品產業,也逐漸走向消費兩極化,高價位的百貨公司專櫃保養品,講究的是消費質感和流行時尚,這塊市場永遠都會存在;平民化消費的開架商品,因為醫學美容保養品的加入,不走時尚路線,而強調使用效果,將美容保養品的大餅愈做愈大。高敏航表示,醫美保養品最早是從歐美開始流行,皮膚較為敏感脆弱的人,在經過皮膚科醫師診斷後,從發病時的投藥,到癒後使用醫學美容保養品護理,讓問題皮膚不再繼續困擾,使得醫學美容成為一塊獨立的領域。儘管美容保養品因為景氣變化產生消費兩極化,但高敏航表示,追求天然有機,不含化學添加物,讓肌膚使用無負擔,是不論高低價位產品,共同研發的趨勢。對注重皮膚保養的使用者來說,換品牌使用陌生的產品並不容易。高敏航指出,開架式的購物平台及網路美容資訊的發達,讓醫美產品加速進入一般消費市場。現在的醫美產品,大多在一般的藥粧通路銷售,而藥粧通路多採開架的方式陳列商品,並有藥師駐店提供諮詢。當消費者需要產品諮詢時,駐店藥師可以立即協助提供專業說明,降低消費者的不信任感,卸下心防願意嘗試。網路美容資訊的快速流通,也是醫美產品擴大消費者信賴的管道之一。高敏航表示,現在消費者蒐集情報的能力很驚人,只要將產品名稱當成關鍵字搜尋,消費者就可以在網路上,找到關於產品的評價,這些素人消費者試用的心得報告,將產品好壞赤裸呈現,足以影響消費者的購買意願,這讓很多原本並不知名的醫美品牌,快速在主要消費客群中傳播,讓醫美保養品得以在品牌眾多的美妝保養品市場,迅速累積人氣,並轉換為實際業績。
Cracking Down on Anti-Aging Claims….!
FDA is Cracking Down on Anti-Aging Claims, Says SpecialChem Speaker, Dr. Norman Estrin (Estrin Consulting Group LLC) SpecialChem - Apr 5, 2012 On March 27, 2012, the FDA Published a new Import Alert, Alert #66-38 for "Skin Care Products Labeled As Anti-Aging Creams".
Anti-Aging Creams The FDA established a "Yellow List" in 1988 of companies with exaggerated "anti-aging" claims. The list has grown since then and now includes multiple products from companies from 17 countries. At that time, "the FDA Associate Commissioner for Regulatory Affairs informed the manufacturers that any products found to be in substantial violation of the new drug and misbranding provisions of the Federal Food, Drug, and Cosmetic Act and may be subject to regulatory action without prior notice". Some companies, at the time, did receive regulatory letters but nothing much appeared to happen until now. The FDA alerted district staff that, "All entries of skin care products imported by the firms or manufactured/shipped by the firms on the Yellow List until for this alert should continue to be checked for drug claims until a district is convinced the firm's products are in compliance". Furthermore, The district was advised that, "Surveillance of entries of skin care products from other importers is also indicated". Get expert advice to develop cosmetic claims with a lower regulatory risk: US Cosmetic Claims: How to be attractive yet non-misleading? Online short course on Thu. May 10, 2012 The new Import alert includes an updated Yellow List, which identifies those firms that more recently received regulatory letters because FDA believes they may be importing these skin care products with drug claims.
The "exaggerated anti-aging" claims include: "counteract", "retard", or "control" the aging process "rejuvenate", "repair", or "restructure" the skin "molecules absorb and expand, exerting upward pressure to 'lift' wrinkles upward"